🇺🇸 FDA
Pipeline program

TD-6450

0094

Phase 1 small_molecule completed

Quick answer

TD-6450 for Hepatitis C is a Phase 1 program (small_molecule) at Theravance Biopharma with 2 ClinicalTrials.gov record(s).

Program details

Company
Theravance Biopharma
Indication
Hepatitis C
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials